[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
Purchase Options:
[Skip to Content Landing]
Views 1,514
Citations 0
November 19, 2014

Drug Derivation Clarified

JAMA. 2014;312(19):2045. doi:10.1001/jama.2014.14363

In the Viewpoint entitled “Drugs for Macular Degeneration, Price Discrimination, and Medicare’s Responsibility Not to Overpay” published in the July 2, 2014, issue of JAMA (2014;312[1]:23-24. doi:10.1001/jama.2014.6672), the description of ranibizumab as the Fab portion of bevacizumab in the second paragraph was not accurate. The sentence should have read: “After bevacizumab was introduced, the manufacturer, Genentech, received approval from the US Food and Drug Administration (FDA) for a genetically engineered variant of the Fab portion of bevacizumab to be used in small doses intraocularly to treat neovascular AMD.” The article was corrected online.